APA
MTNB icon

American Portfolios Advisors’s Matinas BioPharma MTNB Stock Holding History

American Portfolios Advisors’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1
Closed -$428 – 2877
2019
Q2 		$428 Hold
1
– – ﹤0.01% 2660
2019
Q1 		$545 Buy
+1
New +$808 ﹤0.01% 2529

Other funds holding MTNB

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Raymond James Financial Services Advisors
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

American Portfolios Advisors's MTNB Position: Q3 2019 in Review

American Portfolios Advisors sold out of Matinas BioPharma (MTNB) in Q3 2019, closing a stake of 1 share — an estimated $428 sold.

American Portfolios Advisors first reported a position in MTNB in Q1 2019 and held it in 2 quarters. The position peaked at $545 in Q1 2019. 35 funds tracked by Wall St. Rank hold MTNB as of Q3 2019.

  • American Portfolios Advisors reported no remaining Matinas BioPharma position as of Q3 2019 after selling out during the quarter.
  • American Portfolios Advisors sold 1 Matinas BioPharma share in Q3 2019, an estimated $428.
  • American Portfolios Advisors first reported a position in Matinas BioPharma in Q1 2019 and held it in 2 quarters.
  • American Portfolios Advisors's Matinas BioPharma position peaked at $545 in Q1 2019.
  • 35 funds tracked by Wall St. Rank held Matinas BioPharma as of Q3 2019.

Based on American Portfolios Advisors's 13F filing for Q3 2019, filed 24 Mar 2023.